Introduction
Rheumatoid arthritis (RA) is a disease characterised by inflammation of the synovial membranes and subsequent destruction of the underlying cartilage and bone. A variety of animal models of RA have been developed and although none has all the characteristics of the human disease, collagen induced arthritis (CIA) induced by immunisation with type II collagen (CII) has many of the features of RA. The pattern of joint involvement in RA and CIA is similar with the affected joints showing thickening of the synovium by cell proliferation and infiltration, cartilage destruction and pannus formation. 1, 2 In RA, granulocytes enter the synovial fluid and mononuclear cells (including a significant proportion of macrophages) infiltrate the synovium. Depletion of phagocytic cells, either systemically 3 or intra-articularly 4 results in long-term amelioration of experimental arthritis demonstrating the importance of the macrophage in experimental disease. The involvement of the monocyte derived pro-inflammatory cytokines tumour necrosis factor ␣ (TNF␣), interleukin-1 (IL-1) and IL-6 has been demonstrated in both RA [5] [6] [7] and CIA. 8, 9 During the remission phase of CIA significant amounts of IL-10 are produced 8 and IL-10 has been demonstrated in the RA synovium 10 alongside other regulatory cytokines (interleukin 4 and transforming growth factor ␤; TGF␤) and cytokine inhibitors (IL-1ra and soluble TNF receptors). [11] [12] [13] The presence of both pro-inflammatory cytokines and their inhibitors ing the inflamed paws. Human IL-10 mRNA was also detected in the paws 24 h after injection. IL-10 protein was below the level of detection in paws and serum but was detected in some tissues up to 10 days after injection. The target cell of transfection was demonstrated to be the macrophage. These results suggest that systemic therapy with plasmid DNA complexed with cationic liposomes merits further development as an alternative method for antiinflammatory treatment of arthritis. Gene Therapy (2000) 7, 967-977.
suggests that there is a natural balance between cytokines and their inhibitors and that this balance is disturbed during periods of inflammation.
Attempts at therapy using cytokine inhibitors have been successful in animal models and in a clinical setting. Targeting either IL-1␣ and ␤ or TNF␣ by monoclonal antibody infusion produced significant amelioration of disease in CIA 14, 15 and in clinical trials anti-TNF␣ produced significant short-term alleviation of symptoms in RA. 16, 17 Investigators have also addressed the potential therapeutic role of regulatory cytokines and several studies have shown that IL-10 protein administered systemically before or at the time of onset of the symptoms of CIA resulted in significant amelioration of disease. [18] [19] [20] However, for this approach to be effective daily injections of at least 5 g of recombinant IL-10 were required.
Whilst the transient nature of therapy with monoclonal antibodies or recombinant cytokines is well recognised, 21 the potential of gene therapy in the treatment of inflammatory conditions has not generally been well investigated to date. The exception to this is the series of studies and ongoing phase I clinical trial led by Robbins and Evans which have demonstrated the applicability of anticytokine therapy in models of arthritis. [22] [23] [24] [25] However, the methodology employed in these studies requires intraarticular injection of ex vivo infected synovial cells directly into the affected joints. 22, 24 Since RA is a systemic disease it is preferable to develop a delivery vehicle to carry the therapeutic gene to the joint or other sites of inflammation.
Although the aetiology of arthritis is unknown, it is evident from the depletion studies 3, 4 that macrophages are critical for the development of CIA. Macrophages readily take up liposomes 26 and this ability has been exploited to deplete macrophages in vivo using liposome encapsulated cytotoxic drugs 3 and to visualise sites of active inflammation in patients with RA or in experimental arthritis through the use of radiolabelled liposomes. 27 Liposomes need not be injected locally since in the adjuvant arthritis model of RA, methotrexate conjugated liposomes were effective in reducing joint swelling even if delivered intravenously, due to the uptake of the liposomes by inflammed tissue of the joint. 28 However, these studies used large, neutral liposomes and the potential of cationic liposomes to deliver genes to sites of inflammation has not been previously addressed. In this study we have investigated the potential of cationic liposomes to deliver a therapeutic gene to areas of inflammation using a novel formulation of liposomes. Our results suggest that uptake does indeed occur at inflamed sites and that this treatment has a significant beneficial impact on the course of CIA in DBA/1 mice.
Results
Efficient in vitro transfection using ACHx/DC-Chol:DOPE liposomes A previous study examined the efficiency of gene delivery mediated by liposomes formulated from a systematic series of polyamine analogues of DC-Chol (3␤-[N-(NЈ,NЈ-dimethylaminoethane) carbamoyl] cholesterol). 29 Liposomes formulated from several of these analogues gave higher levels of transfection in vitro and in vivo than DC-Chol:DOPE (DC-Chol with dioleoyl L-␣-phosphatidylethanolamine) liposomes, including liposomes formulated from analogue ACHx (3-aza-NЈ-cholesteryloxycarbonyl hexane 1,6-diamine; Figure 1 ) which was selected for further study here. In the earlier report, 29 the cell line CFT1 was used for in vitro transfec- Figure 1 Structural formulae of the cytofectins used in this study.
tion and here we demonstrate that liposomes incorporating ACHx were able to transfect the mouse macrophage cell line (J774) by staining for ␤-galactosidase activity after transfection of J774 cells with the plasmid pCMV␤. Cells were examined under phase contrast illumination in order to distinguish cells producing ␤-galactosidase from those that absorbed the X-gal product after fixation. Figure 2 shows that using 10 g of pCMV␤ complexed with 48 g (40 l) ACHx/DCChol:DOPE liposomes, greater than 90% of cells were transfected and that if the amounts of plasmid and liposomes were increased to 15 g and 72 g (60 l), respectively, staining for ␤-galactosidase appeared more intense, although this was not quantified. In three further experiments (using separate preparations of liposomes) transfection efficiency with ACHx/DCChol:DOPE liposomes was greater than 90% as determined by in situ ␤-galactosidase staining. 
969
The effect of in vivo IL-10 gene delivery on the course of CIA In order to investigate the effect of gene delivery in vivo we compared two plasmids expressing human IL-10 cDNA. The two vectors pcI and pcD differ only in their promoter usage: pcI has a CMV I-E promoter with human ␤-globin intron and pcD has a SV40 promoter and HTLV-1 LTR. Both plasmids expressed human IL-10 protein when transfected into J774 cells in culture. However, transfection of equal amounts of the two plasmids produced different levels of IL-10 in the culture supernatant, 1.9 ng/ml by pcI Hu IL-10 and 3.6 ng/ml by pcD Hu IL-10. Using a mouse model of arthritis enabled us to study the effect of treatment on active disease and by using human rather than endogenous IL-10 we were able to trace the distribution of the transgene after injection. Two to 4 days after the first appearance of arthritis (erythaema and slight swelling) mice with CIA were treated by intraperitoneal (i.p.) injection of plasmid complexed with ACHx/DCChol:DOPE liposomes (0.3 mg plasmid with 0.72 mg liposomes). The plasmids used for treatment were pcI HuIL-10 (number of mice per group, n = 8 ), pcD HuIL-10 (n = 6) or control plasmid (pcI vector; n = 9) and a fourth group of mice (n = 6) remained untreated. Mice were assessed daily for the degree of arthritis for the first 2 weeks, after which time the animals were assessed less often and assessment was no longer blinded. Mice injected with control plasmid and liposome complexes showed a transient drop in disease activity immediately following injection but full disease returned by day 6 and paw swelling reached a maximum of 113% of the day 0 value on day 8 (1.8 mm ± 0.4; Figure 3a ). Mice treated with pcI HuIL-10 plasmid also showed a transient recovery followed by a return to disease, not significantly different from that of the pcI vector group (Figure 3a and b). Untreated mice were followed for the first 3 weeks and the course of disease in this group was similar to the pcI vector treated mice in terms of paw swelling and worse as judged by the grade of arthritis.
In contrast, injection of the expression plasmid pcD HuIL-10 to CIA affected mice had a substantial affect on the course of disease. There was an immediate fall in disease activity (similar to pcI vector and pcI Hu IL-10 treated mice) but the reduction in paw swelling was sustained, down to 27% at day 6 (0.3 mm ± 0.1) and 18% at days 14 to 30 (0.2 mm ± 0.1). The reduction in swelling was significant at day 8 and 9 (P Ͻ 0.01 compared with pcI vector; Figure 3a ). After day 10 there was a marked difference in paw swelling between the pcI vector and pcD Hu IL-10 treated groups, but this was not significant due to the fall in swelling in the pcI vector treated mice. This improvement was also observed for the grade of disease (reduced to 44% at day 9 or grade of 1.2 ± 0.3 and 37% at day 14 to 27 or 1.0 ± 0.5; Figure 3b ). For the period up to 30 days, four out of nine animals treated with pcI vector showed arthritis spreading to additional limbs whereas five out of six of the pcD HuIL-10 group remained free of disease for up to 1 month. However, on day 30-35, disease returned to three out of six of the pcD HuIL-10 group of mice, spreading to additional limbs and increasing both paw swelling and the grade of disease (Figure 3a and b). The number of limbs affected by arthritis in these mice was also recorded in this experiment but no differences were obvious between the groups. The number of affected limbs in the untreated, Gene Therapy pcI vector, pcI HuIL-10 and pcD HuIL-10 treated groups was 1.3 ± 0.2, 2.0 ± 0.2, 1.4 ± 0.2 and 2.0 ± 0.3, respectively, at day 0; and 2.0 ± 0.3, 1.4 ± 0.2, 0.9 ± 0.3 and 0.8 ± 0.4 at day 9. Histological examination was performed on paws to assess if there was any evidence of a protective effect of treatment with pcD Hu IL-10 on the joints. Paws taken from mice injected with pcI vector or pcD Hu IL-10 at the same time after the onset of arthritis and with equivalent grade of disease were examined after 1 month for evidence of joint erosions (Table 1) . Five joints from pcI vector and four joints from pcD Hu IL-10 treated mice were examined. Two of four paws of the IL-10 treated group showed an improvement in the grade of arthritis; none of the control group did. In spite of this improvement in the grade of arthritis, limited histological assessment did not show any difference in the extent of joint erosions between the pcI vector and pcD Hu IL-10 treated groups of mice.
In a second experiment mice with active CIA of 2-4 days standing were injected with either pcD vector (n = One month after the onset of arthritis and treatment paws were graded for arthritis before removal for histological examination. One PIP joint from each paw was assessed blinded for the degree of synovitis.
Results given are the number of paws or joints.
6) or pcD HuIL-10 (n = 5) complexed with ACHx/DCCChol:DOPE liposomes or were left untreated (n = 6). Animals were examined blind for 2 weeks and assessed for limb involvement, the degree of swelling and the grade of disease. In pcD vector treated mice or those remaining untreated disease progressed for the duration of the experiment with an increase in mean paw swelling from 100% (0.9 mm ± 0.2 and 1.0 mm ± 0.2, respectively) at the time of injection to 167% and 150% (1.5 mm ± 0.3) on day 8 or 9. The grade of arthritis in these two groups also increased, from 100% (grade of 1.7 ± 0.2 and 1.9 ± 0.4) at day 0 to 159% (2.7 ± 0.6) and 158% (3.0 ± 0.8) by day 8. The course of disease in the pcD HuIL-10 injected mice showed a quite different pattern with both paw swelling and the grade of arthritis declining for the first week after treatment. In this group, paw swelling and grade were reduced to 33% (0.2 mm ± 0.1) and 50% (grade of 0.8 ± 0.2), respectively, on day 6 and remained lower than in the pcD vector treated group for 2 weeks. The reduction in grade of arthritis was significantly lower in the pcD HuIL-10 treated group compared with the vector group at day 8 (P Ͻ 0.05). These results therefore show a transient therapeutic effect of treatment with the human IL-10 expression vector and comparison of the two vectors pcI Hu IL-10 and pcD Hu IL-10 suggests that the therapeutic effect is likely to be dose dependent.
Distribution of human IL-10 plasmid, cDNA and protein in mice with CIA Following administration of the human IL-10 plasmid pcD Hu IL-10 complexed with ACHx/DCChol:DOPE liposomes, the tissue distribution of plasmid and mRNA product of the transgene were detected by PCR and RT-PCR, respectively. The PCR primers were designed such that they would not detect murine IL-10 DNA. Mice with active CIA were injected i.p. with 0.3 mg of pcD Hu IL-10 complexed with 0.72 mg of ACHx/DCChol:DOPE liposomes and two mice were killed for tissue sampling at each time point from 24 h to 1 month after injection. Twenty-four hours after injection, human IL-10 plasmid was present in the liver, kidney, spleen, lung and paws of mice although not in the draining (inguinal) lymph nodes of the arthritic limbs (Figure 4a ) nor in the tissues of mice injected with control plasmid (pcD vector) complexed with liposomes ( Figure 4d ). PCR was further performed on tissues taken 2, 5, 10, 15 and 30 days after injection. A similar pattern of expression was seen on day 2, although only one of two paw samples had detectable human IL-10 DNA. On days 5, 10 and 15 human IL-10 DNA was detected in liver, kidney, spleen and lung and by day 30 only in spleen and lung (Figure 4b , c and data not shown).
In order to detect human IL-10 mRNA it was necessary to treat tissue RNA preparations with DNase before reverse transcription of the RNA to remove plasmid which co-purifed with the RNA. Destruction of plasmid was confirmed by PCR of DNase treated RNA before the RT step. Human IL-10 cDNA was detected in kidney, spleen and paw 1 day after injection of pcD Hu IL-10 plasmid (Figure 5a ) and for up to 7 days (data not shown) but not in control plasmid injected mice (Figure 5b ). Human IL-10 protein in tissue homogenates was detected by a species specific ELISA. Expression of protein was highest in the kidney on days 1 and 2 (1300 pg/g tissue on day 1) and detectable up to day 10 in other tissues (spleen, liver and lung).
Peritoneal macrophages are transfected by intraperitoneal injection
It was anticipated that intraperitoneal injection of plasmid complexed with ACHx/DCChol:DOPE liposomes would transfect macrophages at the site of injection. 26 To investigate this, smears of peritoneal cells were stained by in situ hybridisation (ISH) using a probe specific for human IL-10 DNA, following i.p. injection of pcD Hu IL-10 complexed with ACHx/DCChol:DOPE liposomes. Peritoneal cells taken from an animal that had been injected with pcI vector complexed with liposomes 4 h earlier were used as a control for non-specific staining by ISH and these cells did not stain with the human IL-10 probe (Figure 6a ). Immediately after injection of pcD Hu IL-10 complexed with liposomes large amounts of extracellular plasmid was detected in the peritoneal fluid, as well as adhered to the majority of the cells (Figure 6b) . Thirty minutes later, there was less extracellular plasmid and more cells with positive stained cytoplasm ( Figure  6c ) and after 4 h the ISH staining was mainly intracellular (Figure 6d ). The number of peritoneal cells staining for human IL-10 plasmid at 4 h by this procedure was 46%. By 24 h after injection the number of IL-10 DNA stained PEC had decreased to 18% (Figure 6e) .
In order to see if macrophages were the cells transfected, peritoneal cells were double stained for human IL-10 DNA by ISH and expression of CD11b (Mac-1; a marker of monocytes 
Discussion
Although initially conceived of as a means of replacing defective genes, gene therapy has now moved into areas of medicine that involve manipulation of pathological responses 31 including the immune response. 32, 33 In inflammatory conditions such as arthritis, the proinflammatory cytokines are essential for disease expression and are obvious targets for antibody and gene therapy. A variety of gene therapy protocols has been tried in an attempt to control experimental arthritis and a human clinical trial is currently in progress. However, in only a few previous reports has a gene therapy protocol succeeded in controlling established arthritis. Previous studies have shown that it is possible to have a moderate impact on the severity and incidence of arthritis by pre-treating mice induced for CIA before the onset of symptoms with xenogeneic cells expressing IL-4 or IL-13. 34 Similarly, pre-treatment with recombinant adenovirus encoding viral IL-10 also delayed the onset and reduced the severity of subsequent arthritis. [35] [36] [37] However, this treatment regime was of no benefit when tested in established arthritis. 36 Moreover, the adenoviral vectors currently in use are known to produce an immune response themselves, 38 thus limiting their application, particularly in an inflammatory condition, where intra-articular injection exacerbates inflammation. 36, 39 By comparison, intramuscular injection of naked plasmid encoding IL-10 or TGF␤ resulted in long-term suppression of cutaneous inflammatory lesions or experimental arthritis. 40, 41 This suggests that a more effective approach to the treatment of chronic inflammatory conditions may be the use of a system that avoids immune reactions.
Since macrophages are essential for the development of CIA as demonstrated by depletion studies 3,4 and macrophages are the major source of pro-inflammatory cytokines in the arthritic synovium 42 these cells would be appropriate targets for gene therapy. Neutral or anionic liposomes, particularly if large, have been used to deliver drugs to macrophages in a variety of studies [43] [44] [45] and have been shown to traffic to sites of inflammation. 27, 46 Such liposomes however are unsuitable for DNA delivery. Cationic liposomes, however, have been proven in other studies to deliver therapeutic genes in sufficient quantity to have a biological affect in conditions such as cystic fibrosis 47 or endotoxic shock. 48 They have been shown to be well tolerated in mice 49 and nonimmunogenic when delivered intraperitoneally 50 or intraarticularly 51 and our results show that ACHx/DCChol: DOPE liposomes are also well tolerated in vivo. In previous studies the transfection efficiency was not significantly greater with ACHx formulated liposomes than DCChol:DOPE liposomes. 29 , 52 Yet we have shown that a significant therapeutic effect was obtained in mice with CIA when ACHx/DCChol:DOPE liposomes were used for in vivo gene delivery.
Whalen et al 37 demonstrated that intravenous administration of adenoviral vector resulted in transgene expression in serum, lung and liver for 3 days, whereas i.p. injection led to preferential expression in the spleen and less expression in serum. In our experiments utilising cationic liposomes, human IL-10 mRNA was detected in the paws 24 h after i.p. injection and IL-10 protein was detected in several tissues, particularly the kidney for 10 days after injection. There was some discrepancy in detecting human IL-10 plasmid, mRNA and protein and this probably reflects the difficulty in extracting sufficient mRNA and protein from tissues for the detection methods used here. However results of these distribution studies suggest that after i.p. injection plasmid is rapidly distributed to distant tissues, is transcribed and human IL-10 protein is synthesised in these tissues but is not released into the serum.
It is recognised that the route of administration can determine the in vivo distribution of plasmid/liposome complexes. Previous studies by Philip et al 53 and Liu et al 54 have shown that intravenous and intraperitoneal injections of plasmid/cationic liposome complexes produce reporter gene expression in many tissues including heart, liver, kidney and spleen. Lung tissue was only transfected by i.v. administration and lymph nodes only transfected after subcutaneous injection. 55 However, it has not been previously reported that cationic liposomes can deliver plasmid to distant sites of inflammation and the mechanism of this delivery could be of therapeutic importance. Our results demonstrate the expected influx of monocytes and polymorphonuclear cells after i.p. injection of plasmid complexed with liposomes and rapid adherence and uptake of IL-10 plasmid to these cells. Moreover, CD11b positive cells recovered from the peritoneal fluid 4 h after injection co-stained by in situ hybridisation for human IL-10 DNA indicating that monocytes were transfected after i.p. injection. Whether the distal localisation to the paws is the result of circulation of these monocyte/macrophages or is due to adherence of the plasmid/liposome complexes to blood mononuclear cells is unknown.
One mechanism by which macrophages auto-regulate pro-inflammatory cytokine production is through the release of IL-10 56 and there is good evidence that IL-10 functions as an anti-inflammatory agent in many situations 57, 58 including arthritis. 18, 19 Our results demonstrate that mice with established CIA treated with IL-10 expression plasmid complexed with liposomes were improved in terms of paw swelling and grade of disease compared with control treated mice. The rapid fall in disease activity, with an obvious reduction in swelling after just 24 h is consistent with the detection of human IL-10 cDNA and protein expression in the tissues 24 h after injection of plasmid/liposomes complexes. The reason for the initial drop in disease activity in the control group Gene Therapy of mice given vector plasmid is uncertain. It may be related to an effect on macrophage function of the liposomes themselves since DC-Chol-containing liposomes can reduce inflammation by interfering with macrophage nitric oxide and TNF production 59 or toxicity of that particular preparation of liposome-DNA complexes. However, the effect of transfection with IL-10 expression plasmid was over and above this non-specific effect and the reduction in disease was sustained. One month after injection of pcD HuIL-10, five of six mice remained almost free of disease and only one had moderate arthritis. Only at about day 30 did disease return in three out of six mice in this group. Since mice treated with the same amount of the plasmid pcI HuIL-10 (which expressed less IL-10 in tissue culture) showed only slight suppression of disease, our results suggest that amelioration of disease is related to the amount of IL-10 produced. Because of the possible effect on macrophage function of the DNA/plasmid lipoplexes themselves it was important that all injections used the same amount of plasmid and liposomes to control for this. The amounts of plasmid and liposome complexes used for in vitro transfections was high and this may explain the high percentage of cells transfected but also demonstrates that toxicity of this formulation of liposomes was generally low. The amount used for in vivo transfections is comparable to that used in similar studies. 48, 60 It is uncertain if the prolonged amelioration of CIA observed was due to the continued expression of human IL-10 protein. Plasmid was detected in spleen and lung for as long as the amelioration lasted (30 days after injection), but IL-10 protein was not detected after 10 days. It is possible that a level of IL-10 production below the limit of detection (50 pg/g tissue for IL-10 protein) was still able to affect ongoing inflammation, particularly if the cells secreting human IL-10 were in part responsible for maintaining the inflammation. A second hypothesis to explain the prolonged amelioration of CIA is that release of a significant amount of IL-10 (a Th2 cytokine) early on in CIA may have altered the developing Th1 like T cell response. This may be the explanation for the findings of Bessis et al 34 who demonstrated that IL-4 and IL-13 expressing CHO cells injected subcutaneously into CII primed mice suppressed the subsequent development of CIA. It is unlikely that in an immunocompetent animal the transplanted xenogeneic cells would be tolerated for long periods but it is possible that the transient production of IL-4 or IL-13 early on was sufficient to alter the developing Th1 like T cell response. In addition, other experimental treatments for CIA such as the use of nondepleting anti-CD4 antibodies 61 or priming with CII in Freund's incomplete adjuvant 8, 62 have been suggested to exert their ameliorating effect by stimulating preferentially the development of Th2 cells and production of Th2 cytokines. However, unlike the studies reported here, none of these experiments were performed in animals with established and inflammatory arthritis. The observation that IL-10 DNA treated mice used in our experiments eventually suffered a relapse of CIA suggests that the underlying disease process was kept in check by the procedures used but was not eliminated.
In summary, we have demonstrated for the first time that cationic liposome-mediated gene delivery is a viable method for the delivery of therapeutic genes to distant inflammatory sites, and that the transgene is expressed in sufficient quantity to have a beneficial effect on established arthritis.
Materials and methods

Expression plasmids
Two types of expression plasmids for IL-10 were used in this study: pcD (which contains a SV40 promoter) containing human IL-10 cDNA was generously provided by Dr Y Chernajovsky (Kennedy Institute of Rheumatology, London, UK). To generate control pcD vector, the IL-10 cDNA was excised with XhoI. The second expression plasmid used was pcI neo (Promega, Southampton, UK, in which the promoter is from CMV) and a PstI to BamHI full length human IL-10 cDNA was cloned into pBluescript and subsequently into the EcoRI and XbaI sites of pcIneo. The plasmid pCMVb was obtained from Clontech (Palo Alto, CA, USA).
Plasmid DNA was isolated by the method of Wicks et al. 63 Briefly, overnight cultures of bacteria were centrifuged and the pellet resuspended in 20% sucrose, 50 mm Tris pH 8 with lysozyme (0.8 mg/ml) and incubated on ice for 5 min. EDTA pH8 was added to 60 mm and after a further 5 min on ice Tris pH 8 was added to 50 mm and the suspension incubated for 10 min at 37°C. The resulting spheroblasts were then lysed by alkaline lysis and plasmid was isolated by Qiagen purification according to the manufacturer's instructions (Qiagen, Dorking, UK). For in vivo transfection an additional caesium chloride gradient purification step was also carried out. Following extensive washing in 70% ethanol, plasmid DNA was redissolved in TE with 150 mm sodium chloride (TE is 10 mm Tris pH 8, 1 mm EDTA pH 8) at 2 mg/ml and treated with End-X (Charles River Endosafe, Margate, UK). Endotoxin contamination of plasmid was determined using the LAL assay (Associates of Cape Cod, Liverpool, UK) and was typically less than 0.3 endotoxin units/ml.
Formulation of cationic liposomes
Structural formulae are shown in Figure 1 . DCChol:-DOPE liposomes were prepared by adding 6 mol of 3␤-[N-(NЈ,NЈ-dimethylaminoethane) carbamoyl] cholesterol (DCChol) and 4 mol of dioleoyl L-a-phosphatidylethanolamine (DOPE) (supplied at 10 mg/ml in CHCl 3 by Sigma, Poole, UK) to freshly distilled CH 2 Cl 2 (5 ml) under nitrogen. DC-Chol was prepared in the manner as described by Alton et al. 64 Following this, sterilised 20 mm NЈ-(2-hydroxyethyl) piperazine-NЈ-(2-ethanesulfonic acid) (HEPES; Sigma) buffer pH 7.8 (5 ml) was added and the mixture sonicated for 3 min. Organic solvents were removed under reduced pressure and the resulting liposome suspension was then sonicated for a further 3 min.
ACHx/DCChol:DOPE liposomes were formulated from 3-aza-NЈ-(cholesteryloxycarbonyl) hexane 1,6-diamine (ACHx), DCChol and DOPE. ACHx was synthesised as described previously. 29 ACHx (2.4 mg, 4.5 mol), DC-Chol (0.75 mg, 1.5 mol) and DOPE (0.3 ml, 3 mg, 4 mol; 10 mg/ml in CHCl 3 by Sigma) were combined in freshly distilled CH 2 Cl 2 (5 ml) under nitrogen, before addition of HEPES buffer, sonication and solvent removal, as above. Liposome preparations were stored at 4°C before use.
Cell culture J774 cells (a mouse macrophage line) were kindly donated by Dr J Raynes (London School of Hygiene and Tropical Medicine) were maintained in RPMI + 5% FCS. For the transfection studies cells were allowed to adhere overnight and washed with Hank's buffered salt solution (HBSS) just before transfection.
Transfections
For in vitro transfections 10 or 15 g of pDNA was mixed with the appropriate amount of undiluted liposomes (1.2 mg/ml) at the ratios shown, incubated for 10 min at room temperature and added to washed adherent cells in 1 ml of HBSS. After 1 h at 37°C the HBSS was replaced with RPMI + 5% FCS and the cells incubated for 24 h before harvesting for the in situ ␤-galactosidase or 48 h before harvesting supernatants for IL-10 ELISA. For in vivo transfections 0.3 mg of plasmid was mixed with 0.72 mg of ACHx/DCChol:DOPE liposomes (1.2 mg/ml), incubated for 10 min and injected intraperitoneally.
In situ ␤-galactosidase assay Cells were washed twice with phosphate buffered saline (PBS), fixed with 2% glutaraldehyde for 1 h and incubated with X-gal solution (0.2% X-gal, 10 mm sodium phosphate pH 7, 150 mm sodium chloride, 1 mm magnesium chloride, and 3.3 mm each of potassium ferricyanide and potassium ferrocyanide) for 1-4 h. For viewing and storage the staining solution was replaced with 70% glycerol.
ELISA
Human IL-10 was detected by a capture assay using an antibody pair (18551D and 18562D Pharmingen, Cambridge Bioscience, Cambridge, UK) following the manufacturer's protocol. Briefly, ELISA plates (Costar 3590, Corning, NY, USA) were coated with capture antibody (18551D) at 1 g/ml (in 0.1 m Na 2 HCO 3 pH 8.2), free sites blocked with 3% bovine serum albumin in PBS and test samples incubated overnight at 4°C. Biotin conjugated detection antibody (1 g/ml in PBS 0.05% Tween 20) was applied, followed by avidin-peroxidase (2.5 g/ml; Sigma A3151) and substrate (OPD; Sigma P8287 0.4 mg/ml in 0.05 m citrate phosphate buffer pH 5). Purified, recombinant IL-10 (Pharmingen; 19701V) was used as the standard in this assay. For detection of human IL-10 in murine tissues, weighed pieces of post mortem samples were homogenised in RPMI + 5% FCS, centrifuged and the cleared supernatant applied in the ELISA at 50% dilution and neat (serum was applied at 20% and 10% dilutions).
RT-PCR
Mice were killed by cervical dislocation and tissue samples snap frozen in liquid nitrogen. For the isolation of total cellular RNA, frozen tissue was thawed directly in RNAzol (Biogenesis, Poole, UK) and samples individually homogenised; RNA was precipitated with isopropanol and redissolved in diethyl pyrocarbonate treated water before reverse transcription of 5 g RNA with 100 units Superscript II (Gibco BRL, Paisley, UK). Human IL-10 plasmid (which co-purifies with the RNA in this method) and actin cDNA (as an internal control) were detected by PCR using 2.5 units Taq polymerase (Promega) and 20 pmol each of forward and reverse pri-975 mers of the sequences shown below. Thirty-five PCR cycles were carried out at 95°C for 1 min, 58°C for 1 min, 72°C for 2 min and a final extension of 72°C for 7 min. PCR products were analysed on 1% agarose gels. To detect human IL-10 the following primer pair was used: 5Ј TGAGAACCAAGACCCAGAC 3Ј and 3Ј GGGAACT CTTTGGAATAAC 5Ј yielding a 350 bp product. The actin primer pair had the sequences: 5Ј GTGGGGCGCC CCAGGCACCA 3Ј and 3Ј CTCCTTAATGTCACGCAC-GATTTC 5Ј producing a 548 bp product. For the detection of RNA free of plasmid contamination, the RNA preparation was treated with DNase (5 units for 1 h at 37°C; then 15 min at 72°C with 2 mm EDTA) before reverse transcription.
In situ hybridisation and immunocytochemical staining Primer specific for human IL-10 DNA (5Ј CTGTTCTCA-GACTGGGTGCC 3Ј) was labelled at the 3Ј end with fluorescein-dUTP according to the manufacturer's instructions (Amersham, UK; RPN3400). After i.p. injection of liposome-plasmid complexes mice were anaesthetised and killed by cervical dislocation. 2 ml of HBSS was injected i.p. and peritoneal cells aspirated and stored on ice until cells were pelleted by centrifugation. Cells were resuspended, smeared on to microscope slides, air dried and stored frozen. On thawing, slides were post fixed in 4% paraformaldehyde and treated with 0.25% acetic anhydride in 0.1 m triethanolamine before blocking of endogenous alkaline phosphatase activity by rinsing in cold 20% acetic acid followed by 5 min incubation in 2 mm levamisole. Slides were taken through alcohol to a 5 min chloroform treatment. Fluoresceinated probe was applied to dry slides at 50 ng/ml in 1:1 formamide:hybridisation buffer (Amersham) under coverslips, heated to 90°C for 3 min and incubated for 16-24 h at 37°C. Posthybridisation washes were of 2 × SSC (1 × SSC is 0.15 m NaCl, 0.015 m Na citrate) followed by 1 × SSC at 45°C and slides were further treated with 0.5% blocking agent (Amersham) in Tris buffered saline (TBS) for 30 min. Alkaline phosphatase conjugated anti-fluorescein antibody in 0.5% bovine serum albumin in TBS was applied for 45 min and the substrate of nitroblue tetrazolium/5-bromo-chloro-indolyl phosphate in 100 mm Tris, 100 mm NaCl, 50 mm Mg 2 Cl pH 9.5 (Amersham) applied overnight at RT. Slides were mounted in 75% glycerol and examined and photographed under × 400 magnification.
In some experiments smears of peritoneal cells were additionally stained for the surface marker CD11b. After post-fixation but before in situ hybridisation slides were treated with anti-CD11b (clone M1/70, Pharmingen) or control rat IgG2b antibody. After washing and blocking of endogenous peroxidase with 1% hydrogen peroxide in methanol, horse radish peroxidase conjugated anti-rat IgG was applied in 20% normal mouse serum in PBS followed by diaminobenzidine solution (Sigma D4168; used according to manufacturer's instructions). In situ hybridisation was then performed on the same slides. Slides were mounted in 70% glycerol and photographed under oil immersion.
Induction and assessment of arthritis
Bovine type II collagen (CII) was prepared as described. 65 Male DBA/1 mice of 8-10 weeks were immunised subcutaneously at the base of the tail with 100 g of CII in Freund's complete adjuvant followed 3 weeks later by a Gene Therapy second injection of 200 g in Freund's incomplete adjuvant. Animals were treated with liposome-plasmid preparations 2-4 days after the onset of arthritis. Disease activity was monitored by both paw swelling measured with calipers and grading of disease in each limb (a score of 1 = erythaema or slight swelling; 2 = obvious swelling; and 3 = ankylosis). Mice were assigned at random to the different treatment groups and the degree of swelling and grade of arthritis at day 0 (the day of treatment) for the groups are standardised to 100% to allow comparisons between groups. One month after the onset of arthritis mice were killed and paws that had shown evidence of arthritis were removed, formalin fixed and decalcified before sectioning and staining with haematoxylin and eosin. Sagittal sections of the proximal interphalangeal joint were examined blind for inflammatory infiltrates and erosion of the bone and cartilage. Severity of arthritis was classified as: slight, minimal cellular infiltration with no erosions; mild, minimal synovitis, cartilage loss and bone erosions; moderate, obvious synovitis and erosions but joint intact; severe, extensive cellular infitration and erosions and joint architecture disrupted.
Statistical analysis
The Mann-Whitney rank sum test with Yate's correction was used to assess the effects of treatment on the course of CIA.
